Browsing by Author "Oluwajembola, Abimbola Mary"

Filter results by typing the first few letters
Now showing 1 - 3 of 3
  • No Thumbnail Available
    Item
    A ReviewofNovelCancerTherapeuticsandCurrent Research Trends
    (Wiley The Scientific World Journal Volume 2025, 2025) Oluwajembola, Abimbola Mary; Zakari, Suleiman; Cleanclay, Wisdom D.; Ayeni, Timothy; Adebosoye, Adewale; Okoh, Olayinka S.; Folamade, Joshua; Bawa, Inalegwu; Ogunlana, OlubankeOlujoke
    The uncheckedgrowthandspreadofaberrantcellsdescribeawidelydiversecollectionofdisordersthatcollectivelyconstitute cancer. Conventionaltherapiesforcancer,includingradiationtherapy,chemotherapy,andsurgery,haveincreasedthechances of survivalsignificantly inmostpatients.Thesetraditionalmethodsusuallyresultinlowtumorortumorcellspecificity, significant systemictoxicity,andthedevelopmentofdrugresistance.Thisreviewsummarizesupdatesincancertherapy,some of whichincludecutting-edgetherapiesrepresentedbyCAR-Ttherapy,targetedtherapies,genetherapy,arginine-depriving therapy, mitochondria-targetedtherapies,neutrophil-targetedtherapies,andthelatestPROTACtechnologyforproteolysis- targeting chimera.Ithasemphasizedmechanismsunderlyingthesenewtherapeuticstrategiesandtheirtranslationalpotential for treatinghumancancers.Wefurtherdiscuss,foreachapproach,thechallenges,limitations,sideeffects, anddelivery systems. Thereviewproceedswithadynamicchangeinthelandscapeofcancerresearchinbiology,wheremachinelearning and artificial intelligenceareincreasinglyimportanttoimproveourunderstandingofthemechanismsofcancerandtreatment responses. Wealsodescribethepotentialofstemcelltherapy,metabolomics,andnoveldrugdeliverysystemstowardbetter patient outcomes.Thepaperpullstogethersomeofthecurrentresearch findings andresultsofclinicaltrialsinnew therapeutic developmentsandemergingareasofresearchthatholdoutexcitingpromisesforthefutureprogressofcancer treatment
  • No Thumbnail Available
    Item
    Photosensitizers in photodynamic therapy: An advancement in cancer treatment
    (Results in Chemistry (Elsevier), 2024) Oluwajembola, Abimbola Mary; Cleanclay, Wisdom D.; Onyia, Abimbola F.; Chikere, Bruno N.; Zakari, Suleiman; Ndifreke, Ebong; De Campos, Opeyemi C.
    Photodynamic therapy (PDT) is a clinically proven advancement in cancer treatment that has progressively gained consideration as a possible method of cancer treatment over time. This therapy, which involves the administration of a photosensitizing drug before activation of the drug with light from a source such as a laser to produce a cytotoxic effect, is minimally invasive and could increase the life expectancy of cancer patients. Cancer has been a major threat to human health, and it affects the quality of life of cancer patients as it is one of the topmost causes of mortality worldwide. The burden of cancer has been projected to increase to 2.1 million new cases and 1.4 million deaths in Africa by 2040. It is therefore expedient to put in more effort in proffering preventive measures, more efficient treatments, and possible cures for this disease. Recent studies have shown that many types of tumors can be destroyed using PDT. Tumor cells are destroyed via apoptosis, necrosis, and autophagy through some mechanisms in PDT. The successful outcome of this therapy depends greatly on three components which are photosensitizer (PS), light and molecular oxygen. Out of these three, photosensitizer is the most essential. Among the characteristics of a potent PS are the presence of a tetrapyrrole structure and the ability to initiate a photodynamic reaction when irradiated typically at a wavelength between 600 nm and 800 nm, although some PS can function effectively outside this range. This review highlights the effectiveness of PDT in the treatment of cancer and emphasizes the importance of PS, with more focus on those derived from natural sources, in determining the outcome of the therapy.
  • No Thumbnail Available
    Item
    Targeting c-Met in breast cancer: From mechanisms of chemoresistance to novel therapeutic strategies
    (Current Research in Pharmacology and Drug Discovery, 2024) Iweala, Emeka Eze Joshua; Amuji, Doris Nnenna; Oluwajembola, Abimbola Mary; Ugbogu, Eziuche Amadike
    Breast cancer presents a significant challenge due to its heterogeneity and propensity for developing chemo resistance, particularly in the triple-negative subtype. c-Mesenchymal epithelial transition factor (c-Met), a re ceptor tyrosine kinase, presents a promising target for breast cancer therapy due to its involvement in disease progression and poor prognosis. However, the heterogeneous expression of c-Met within breast cancer subtypes and individual tumors complicates targeted therapy. Also, cancer cells can develop resistance to c-Met inhibitors through various mechanisms, including bypass signaling pathways and genetic mutations. The off-target effects of c-Met inhibitors further limit their clinical utility, necessitating the development of more selective agents. To overcome these challenges, personalized treatment approaches and combination therapies are being explored to improve treatment efficacy while minimizing adverse effects. Novel c-Met inhibitors with improved selectivity and reduced off-target toxicity show promise in preclinical studies. Additionally, targeted delivery systems aim to enhance drug localization and reduce systemic toxicity. Future directions involve refining inhibitor design and integrating c-Met inhibition into personalized treatment regimens guided by molecular profiling. This review explores the mechanisms by which c-Met contributes to chemoresistance in breast cancer and current challenges in targeting c-Met for breast cancer therapy. It discusses strategies to optimize treatment outcomes, ultimately improving patient prognosis and reducing mortality rates associated with this devastating disease